Clinical trial
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous…
NCT00054431 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00054431 |
|---|---|
| Title | Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | Phase II Study of Imatinib Mesylate (Gleevec, STI-571) (NSC#716051) and Decitabine (5-AZA-2'-Deoxycitidine) (NSC#127716), in Chronic Myelogenous Leukemia in Accelerated and Blastic Phases |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Relapsing Chronic Myelogenous Leukemia |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, decitabine, laboratory biomarker analysis |
| Enrollment | 80 |
| Start date | Jan 1, 2003 |
| Primary completion | May 1, 2007 |
| First posted | Feb 6, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: